| 证券代码：301188 | 证券简称：力诺药包 | 公告编号：2025-109 | | --- | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | | 山东力诺医药包装股份有限公司 山东力诺医药包装股份有限公司（以下简称"公司"）于 2025 年 6 月 6 日召开第四 届董事会第十一次会议和第四届监事会第十次会议，审议通过了《关于为全资子公司提 供担保的议案》，同意公司为公司全资子公司山东力诺玻璃科技有限公司（以下简称"玻 璃科技"）向金融机构申请不超过 1 亿元（含本数）的授信额度提供不超过人民币 1 亿 元（含本数）的连带责任保证担保，担保额度自董事会审议通过之日起一年内有效。具 体详见公司于 2025 年 6 月 6 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于 为全资子公司提供担保的公告》（公告编号：2025-058）。 二、担保进展情况 近日，公司全资子公司玻璃科技向中国农业银行股份有限公司商河县支行（以下 简称"农业银行"）申请综合授信额度，同时公司与农业银行签订了《保证合同》（以下 简称"保证合同"），为玻璃科技在农业银行的 ...

Financial Performance - The company's revenue for Q3 2025 was ¥222,287,195.16, a decrease of 17.69% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥9,914,868.97, down 48.32% year-on-year[5]. - The basic earnings per share decreased by 50.00% to ¥0.04[5]. - Total operating revenue for the current period is ¥721,014,626.29, down from ¥830,872,973.77 in the previous period, representing a decrease of approximately 13.2%[19]. - Net profit for the current period is ¥50,882,334.53, a decline from ¥70,471,346.82 in the previous period, reflecting a decrease of approximately 28%[20]. - Basic earnings per share for the current period is ¥0.22, down from ¥0.30 in the previous period, a decrease of about 26.7%[21]. Assets and Liabilities - Total assets increased by 8.71% to ¥2,561,318,259.54 compared to the end of the previous year[5]. - Total assets amount to ¥2,561,318,259.54, an increase from ¥2,356,016,894.42 in the previous period, representing a growth of approximately 8.7%[17]. - Total liabilities are ¥956,977,598.68, up from ¥801,801,927.49 in the previous period, indicating an increase of about 19.4%[17]. - Non-current assets total ¥1,276,732,667.12, compared to ¥977,512,837.13 in the previous period, reflecting an increase of approximately 30.6%[17]. - Current liabilities amount to ¥462,651,820.72, an increase from ¥337,200,557.80 in the previous period, representing a growth of about 37.2%[17]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥60,472,268.24, a decline of 293.85% compared to the same period last year[9]. - The company’s cash flow from financing activities improved to a net inflow of ¥8,758,423.52, compared to a net outflow in the previous year[9]. - Operating cash inflow for the current period was CNY 636,400,328.38, an increase from CNY 623,745,384.60 in the previous period[22]. - Net cash outflow from operating activities was CNY -60,472,268.24, compared to a net inflow of CNY 31,195,830.67 in the previous period[23]. - Cash inflow from financing activities was CNY 87,102,350.92, compared to CNY 724,201.06 in the previous period[23]. - Net cash inflow from financing activities was CNY 8,758,423.52, a significant improvement from a net outflow of CNY -73,717,815.72 in the previous period[23]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,616[11]. - The largest shareholder, Linuo Investment Holding Group, holds 32.16% of shares, totaling 76,895,461 shares, with 56,930,000 shares pledged[11]. - Jinan Hongdao New Energy Partnership holds 6.35% of shares, totaling 15,177,000 shares[11]. - The top ten shareholders include various investment funds and companies, indicating a diverse shareholder base[12]. - The company has not reported any changes in the status of preferred shareholders or significant changes in shareholding due to margin trading[14]. Inventory and Investments - The company reported a significant increase in long-term equity investments by 168.48% to ¥142,261,977.71 due to the purchase of equity in Chuangyang[8]. - The company’s inventory increased by 55.11% to ¥422,960,281.23, attributed to increased production capacity[8]. - Long-term investments increased to ¥142,261,977.71 from ¥52,987,357.77, showing a significant rise of approximately 168.5%[17]. Other Financial Metrics - The company’s financial expenses rose by 35.95% to ¥17,238,659.96, primarily due to a decrease in interest income from reduced investment amounts[9]. - Total operating costs for the current period are ¥684,502,021.07, compared to ¥764,080,029.44 in the previous period, indicating a decrease of about 10.5%[19]. - Research and development expenses for the current period are ¥23,442,506.08, slightly up from ¥22,242,760.16 in the previous period, indicating a growth of about 5.4%[20]. - Total cash and cash equivalents decreased from ¥490,489,588.50 to ¥380,348,094.76, a decline of approximately 22.6%[15]. - Trading financial assets decreased from ¥295,750,585.02 to ¥116,398,478.20, a decline of approximately 60.7%[15]. - Accounts receivable increased from ¥207,803,012.45 to ¥233,866,369.38, an increase of approximately 12.5%[15]. - Prepayments increased from ¥17,214,368.78 to ¥25,040,449.73, an increase of approximately 45.5%[15]. - Other receivables increased from ¥9,526,282.49 to ¥10,373,628.53, an increase of approximately 8.9%[15]. Audit Status - The company has not yet audited its third-quarter financial report[25].

Group 1 - The core point of the article indicates that Linuo Pharmaceutical reported a revenue of 222 million yuan for the third quarter, representing a year-on-year decline of 17.69% [1] - The net profit for the third quarter was 9.91 million yuan, which is a year-on-year decrease of 48.32% [1] - For the first three quarters, the total revenue was 721 million yuan, showing a year-on-year decline of 13.22% [1] - The net profit for the first three quarters amounted to 50.88 million yuan, reflecting a year-on-year decrease of 27.80% [1]

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has experienced fluctuations in stock performance, with a year-to-date increase of 19.08% and a recent decline over the past 60 days of 17.88% [2] Company Overview - Linuo Pharmaceutical Packaging, established on March 1, 2002, and listed on November 11, 2021, is located in Shandong Province, China [2] - The company specializes in the research, production, and sales of specialty glass, focusing on borosilicate glass development and application [2] - Revenue composition includes heat-resistant glass (57.02%), pharmaceutical glass (40.74%), and other material sales (2.24%) [2] - The company operates within the pharmaceutical and biological industry, specifically in medical devices and consumables [2] Financial Performance - For the first half of 2025, Linuo Pharmaceutical reported revenue of 499 million yuan, a year-on-year decrease of 11.07% [2] - The net profit attributable to the parent company was approximately 40.97 million yuan, reflecting a year-on-year decline of 20.12% [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 17.08% to 11,100 [2] - The average number of circulating shares per shareholder decreased by 12.16% to 21,522 shares [2] - Cumulative cash dividends since the company's A-share listing amount to 139 million yuan, with 92.18 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Guotai Junan Value Advantage Flexible Allocation Mixed Fund, which holds 5.90 million shares, a decrease of 1.55 million shares from the previous period [3] - Guotai Junan Innovation Growth Mixed Fund holds 2.87 million shares, down by 530,000 shares [3] - Guotai Junan Pharmaceutical Health Stock A is a new shareholder with 2.79 million shares [3]

Core Viewpoint - Linuo Pharmaceutical (301188) announced the supplementary election of Mr. Gao Yuankun and Mr. Ma Yi as candidates for non-independent directors of the fourth board of directors [1] Company Summary - The company has made a governance change by electing two new non-independent directors to its board [1]

Group 1 - The core point of the article is the resignation of key executives at Linuo Pharmaceutical, including Chairman Yang Zhongchen due to reaching retirement age, and the resignations of directors Li Lei and Wang Quanjun for personal reasons [1] - Following the resignations, Yang Zhongchen will no longer hold any position in the company, while Li Lei will continue as Deputy General Manager, and Wang Quanjun will not hold any position in the company [1] - The company has nominated Gao Yuankun and Ma Yi as new non-independent director candidates to ensure the normal operation of the board [1]

国联民生证券承销保荐有限公司 关于山东力诺医药包装股份有限公司 使用部分闲置募集资金和自有资金进行现金管理的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生"或"保荐机构"） 作为山东力诺医药包装股份有限公司（以下简称"力诺药包"或"公司"）首次 公开发行股票并在创业板上市以及向不特定对象发行可转换公司债券的保荐机 构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等有关规定，对力诺药包使用部分闲置募集资金和自有资金 进行现金管理的事项进行了核查，具体情况如下： 一、募集资金基本情况 （一）首次公开发行募集资金情况 根据中国证券监督管理委员会《关于同意山东力诺特种玻璃股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]3022 号），公司首次公开发行人 民币普通股（A 股）58,109,777 股，每股面值人民币 1.00 元,每股发行价格为 13.00 元，募集资金总额为 75,542.71 万 ...

国联民生证券承销保荐有限公司 关于关联方为山东力诺医药包装股份有限公司 提供担保暨关联交易的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生"或"保荐机构"） 作为山东力诺医药包装股份有限公司（以下简称"力诺药包"或"公司"）向不 特定对象发行可转换公司债券的保荐机构，根据《证券发行上市保荐业务管理办 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关规定，对关联方为力诺药包提供担保暨关联交 易事项进行了核查，具体情况如下： 一、关联交易概况 （一）关联交易的基本情况 公司为推进"力诺药包三期高端药用包材项目"的建设进度，解决项目资金 需求，拟向国家开发银行山东省分行申请 1 亿元银行贷款，贷款期限 5 年。公司 控股股东力诺投资控股集团有限公司的控股股东力诺集团股份有限公司（以下简 称"力诺集团"）为公司本次贷款提供连带责任保证担保，该担保不需要公司提 供反担保，力诺集团将在相关担保事项实际发生时，根据实际担保金额及天数以 年化 1%的费率收取担保费用。 （二）本 ...

股票代码：301188 股票简称：力诺特玻 债券代码：123221 债券简称：力诺转债 国联民生证券承销保荐有限公司 债券受托管理人 中国（上海）自由贸易试验区浦明路 8 号 关于山东力诺特种玻璃股份有限公司 创业板向不特定对象发行可转换公司债券 第三次临时受托管理事务报告 （2025 年度） 二〇二五年十月 重要声明 本报告依据《公司债券发行与交易管理办法》（以下简称"《管理办法》"）《山 东力诺特种玻璃股份有限公司创业板向不特定对象发行可转换公司债券受托管 理协议》（以下简称"《受托管理协议》"）《山东力诺特种玻璃股份有限公司创业 板向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"） 等相关公开信息披露文件，由本次可转债受托管理人国联民生证券承销保荐有限 公司（以下简称"国联民生"）编制。国联民生对本报告中所包含的从上述文件 中引述内容和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确 性和完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为国联民生所作的承诺 或声明。在 ...

二、关于使用部分闲置募集资金和自有资金进行现金管理的核查意见 山东力诺医药包装股份有限公司 第四届董事会独立董事 2025 年第七次专门会议审核意见 根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律、法规和规范性文件以及《公司章程》的有关规定，山东力诺医药包装股份有 限公司（以下简称"公司"）独立董事召开了第四届董事会独立董事 2025 年第七 次专门会议，审议通过了《关于补选第四届董事会非独立董事的议案》《关于使 用部分闲置募集资金和自有资金进行现金管理的议案》《关于公司向银行申请贷 款并由关联方提供担保暨关联交易的议案》。经认真审阅相关材料，并对有关情 况进行详细了解和分析，基于独立判断的立场，秉承实事求是、客观公正的原则， 就公司第四届董事会独立董事 2025 年第七次专门会议相关事项发表审查意见如 下： 一、关于补选第四届董事会非独立董事的核查意见 经审议，独立董事认为：本次补选的非独立董事候选人已征得被提名人本人 同意，候选人符合上市公司董事的任职资格，不存在《公司法》《证券法》《深圳 证券交易所创业 ...